Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 12.7% in August

Capricor Therapeutics Inc (NASDAQ:CAPR) saw a significant growth in short interest in August. As of August 15th, there was short interest totalling 7,000,000 shares, a growth of 12.7% from the July 31st total of 6,210,000 shares. Based on an average daily volume of 425,200 shares, the short-interest ratio is currently 16.5 days.

Analyst Upgrades and Downgrades

CAPR has been the subject of a number of research analyst reports. Oppenheimer initiated coverage on Capricor Therapeutics in a report on Friday, May 17th. They issued an “outperform” rating and a $14.00 target price for the company. LADENBURG THALM/SH SH increased their target price on Capricor Therapeutics from $24.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $8.00 target price on shares of Capricor Therapeutics in a report on Tuesday, May 14th. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, July 2nd. Finally, StockNews.com lowered Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $21.75.

Institutional Trading of Capricor Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new stake in shares of Capricor Therapeutics in the first quarter worth about $40,000. Main Street Financial Solutions LLC lifted its position in shares of Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after buying an additional 7,500 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of Capricor Therapeutics in the second quarter worth about $147,000. Jump Financial LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter worth about $258,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Stock Down 2.8 %

Shares of CAPR opened at $4.57 on Friday. The firm has a market cap of $146.14 million, a price-to-earnings ratio of -5.25 and a beta of 4.00. The company’s fifty day moving average is $4.42 and its 200-day moving average is $5.14. Capricor Therapeutics has a 12 month low of $2.68 and a 12 month high of $7.28.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 231.68% and a negative net margin of 89.72%. The business had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. As a group, research analysts predict that Capricor Therapeutics will post -1.04 earnings per share for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.